Black Diamond Therapeutics (NASDAQ: BDTX) net income
Black Diamond Therapeutics reported a net profit of $22.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $69.7m. Its net margin was 32.0%. Earnings per share were $0.39.
Fiscal 2025 is the highest of the 8 fiscal years on record for Black Diamond Therapeutics. It reported a loss in 7 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $22.4m | — | 32.0% | $0.39 |
| 2024 | −$69.7m | — | — | −$1.27 |
| 2023 | −$82.4m | — | — | −$1.88 |
| 2022 | −$91.2m | — | — | −$2.52 |
| 2021 | −$125.6m | — | — | −$3.47 |
| 2020 | −$67.3m | — | — | −$2.05 |
| 2019 | −$35.3m | — | — | — |
| 2018 | −$8.9m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Black Diamond Therapeutics net income compared with its sector
By net income for its latest fiscal year, Black Diamond Therapeutics ranks 148th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Black Diamond Therapeutics, 32.0%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 146th | Astrana Health | $22.5m | 0.7% |
| 147th | Iradimed | $22.5m | 26.8% |
| 148th | Black Diamond Therapeutics | $22.4m | 32.0% |
| 149th | 908 Devices | $19.5m | 34.7% |
| 150th | Tactile Systems Technology | $19.1m | 5.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Black Diamond Therapeutics
- How much did Black Diamond Therapeutics earn in fiscal 2025?
- Black Diamond Therapeutics reported a net profit of $22.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $69.7m.
- What are the earnings per share of Black Diamond Therapeutics?
- They were $0.39 in fiscal 2025, compared with −$1.27 in fiscal 2024.
- What is the net margin of Black Diamond Therapeutics?
- In fiscal 2025 its net profit was 32.0% of its revenue.
- What was the most profitable year for Black Diamond Therapeutics?
- Of its last 8 fiscal years, fiscal 2025, with $22.4m.
- Where does Black Diamond Therapeutics rank in its sector by net income?
- It ranks 148th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Black Diamond Therapeutics come from?
- From the annual report (Form 10-K) that Black Diamond Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Black Diamond Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Black Diamond Therapeutics: the Black Diamond Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.